Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer

European Urology

Volumn 70, Issue 4, 2016, Pages 611-620

  Guo, Charles Chuanhai ^a   Dadhania, Vipulkumar ^a   Zhang, Li ^a   Majewski, Tadeusz ^a   Bondaruk, Jolanta ^a   Sykulski, Maciej ^b   Wronowska, Weronika ^c   Gambin, Anna ^b   Wang, Yan ^a   Zhang, Shizhen ^a   Fuentes Mattei, Enrique ^a   Kamat, Ashish Madhav ^a   Dinney, Colin ^a   Siefker Radtke, Arlene ^a   Choi, Woonyoung ^a   Baggerly, Keith A ^a   McConkey, David ^a   Weinstein, John N ^a   Czerniak, Bogdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

Author keywords

Expression profile; Micropapillary bladder cancer; Molecular signature; Prognosis

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 296; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; PROTEIN P63; RUVBL1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; AAA PROTEIN; CARRIER PROTEIN; CD44 PROTEIN, HUMAN; CYTOKERATIN 14; DNA HELICASE; GATA3 PROTEIN, HUMAN; HYALURONIC ACID BINDING PROTEIN; KRT14 PROTEIN, HUMAN; MIRN296 MICRORNA, HUMAN; RUVBL1 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN; UPK2 PROTEIN, HUMAN; UROPLAKIN 2;

AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; GENETICS; KAPLAN MEIER METHOD; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; WHOLE GENOME SEQUENCING;

ATPASES ASSOCIATED WITH DIVERSE CELLULAR ACTIVITIES; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; DNA HELICASES; DOWN-REGULATION; GATA3 TRANSCRIPTION FACTOR; HUMANS; HYALURONAN RECEPTORS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KERATIN-14; MICRORNAS; PPAR GAMMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; UROPLAKIN II; WHOLE GENOME SEQUENCING;

EID: 84960969628     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.02.056     Document Type: Article

References (37)

1. [1] Spiess, P.E., Czerniak, B., Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 130 (2006), 844–852.
2. [2] Heney, N.M., Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Am 19 (1992), 429–433.
3. [3] Stein, J.P., Lieskovsky, G., Cote, R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001), 666–675.
4. [4] Takata, R., Katagiri, T., Kanehira, M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11 (2005), 2625–2636.
5. [5] Knowles, M.A., Hurst, C.D., Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15 (2015), 25–41.
6. [6] Choi, W., Porten, S., Kim, S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
7. [7] Nigwekar, P., Amin, M.B., The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol 15 (2008), 218–233.
8. [8] Watts, K.E., Hansel, D.E., Emerging concepts in micropapillary urothelial carcinoma. Adv Anat Pathol 17 (2010), 182–186.
9. [9] Amin, M.B., Ro, J.Y., el-Sharkawy, T., et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18 (1994), 1224–1232.
10. [10] Kamat, A.M., Dinney, C.P., Gee, J.R., et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110 (2007), 62–67.
11. [11] Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. International Agency for Research on Cancer Web site. https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/BB7.pdf.
12. [12] Sobin, L.H., Gospodarowicz, M.K., Wittekind, C., TNM classification of malignant tumours. 2009, Wiley-Blackwell, Hoboken, NJ.
13. [13] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
14. [14] Bernardini, S., Billerey, C., Martin, M., Adessi, G.L., Wallerand, H., Bittard, H., The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 165 (2001), 42–46 discussion 46.
15. [15] Singh, R.R., Murugan, P., Patel, L.R., et al. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod Pathol 28 (2015), 1225–1235.
16. [16] Kramer, A., Green, J., Pollard, J. Jr., Tugendreich, S., Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30 (2014), 523–530.
17. [17] Maia, D., de Carvalho, A.C., Horst, M.A., Carvalho, A.L., Scapulatempo-Neto, C., Vettore, A.L., Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma. J Trans Med, 13, 2015, 262.
18. [18] Kim, J.H., Tuziak, T., Hu, L., et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 85 (2005), 532–549.
19. [19] Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. PNAS 111 (2014), 3110–3115.
20. [20] Dong, D.D., Zhou, H., Li, G., ADAM15 targets MMP9 activity to promote lung cancer cell invasion. Oncol Reports 34 (2015), 2451–2460.
21. [21] Yang, J., Altahan, A.M., Hu, D., et al. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J Natl Cancer Inst, 107, 2015, djv080.
22. [22] Lin, M.Z., Marzec, K.A., Martin, J.L., Baxter, R.C., The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene 33 (2014), 85–96.
23. [23] Sjodahl, G., Lauss, M., Lovgren, K., et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18 (2012), 3377–3386.
24. [24] McConkey, D.J., Choi, W., Shen, Y., et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 69 (2016), 855–862.
25. [25] Nassar, H., Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol 11 (2004), 297–303.
26. [26] Marchio, C., Iravani, M., Natrajan, R., et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215 (2008), 398–410.
27. [27] Weigelt, B., Horlings, H.M., Kreike, B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216 (2008), 141–150.
28. [28] Choi, W., Czerniak, B., Ochoa, A., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Rev 11 (2014), 400–410.
29. [29] McConkey, D.J., Choi, W., Dinney, C.P., New insights into subtypes of invasive bladder cancer: considerations of the clinician. Euro Urol 66 (2014), 609–610.
30. [30] Sjodahl, G., Lovgren, K., Lauss, M., et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 183 (2013), 681–691.
31. [31] Lee, K.H., Lin, F.C., Hsu, T.I., et al. MicroRNA-296–5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim Biophy Acta 1843 (2014), 2055–2066.
32. [32] Savi, F., Forno, I., Faversani, A., et al. miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. Clin Sci 127 (2014), 233–242.
33. [33] Vaira, V., Faversani, A., Dohi, T., et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 31 (2012), 27–38.
34. [34] Wei, J.J., Wu, X., Peng, Y., et al. Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17 (2011), 1297–1305.
35. [35] Nordentoft, I., Birkenkamp-Demtroder, K., Agerbaek, M., et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics, 5, 2012, 40.
36. [36] Gentili, C., Castor, D., Kaden, S., et al. Chromosome missegregation associated with RUVBL1 deficiency. PLoS One, 10, 2015, e0133576.
37. [37] Taniuchi, K., Furihata, M., Iwasaki, S., et al. RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell invasion. Intl J Oncol 44 (2014), 1945–1954.